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short duration of eﬀ ect. Blinatumomab might be useful 
in combinations to obtain even deeper response and 
remissions that are long enough to allow organisation of 
transplantation. Blinatumomab could thus ﬁ nd a place 
in a window period and serve as a bridge to SCT. Several 
factors should be considered for this approach, including 
the likelihood of achieving remission, organ toxic eﬀ ects, 
and the time needed to screen, enroll, and treat patients 
before SCT. Finally, new therapeutic strategies might 
focus on exploiting targets governing stem-cell renewal 
and diﬀ erentiation. An important issue in favour of 
combination therapy is that blinatumomab can target 
bulk leukaemia cells, but not the leukaemia stem cell. 
This supposition is supported by the short duration of 
eﬀ ect with blinatumomab. Furthermore, the ability to 
target sanctuary sites remains a major challenge. 
Many drugs have become available that have the 
potential to change the standard of care for adult patients 
with ALL. Combination of several agents targeting more 
than one antigenic determinant, gene mutation, or 
signal transduction pathway might be the most eﬀ ective 
strategy, and could hold the promise of substantial 
beneﬁ t, and could represent a targeted solution similar 
to the total therapy approach pioneered by Don Pinkel in 
the 1960s with chemotherapeutic agents.
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The International Breast cancer Intervention Study 
(IBIS-I) is a randomised, placebo-controlled chemo-
prevention clinical trial of the eﬀ ects of tamoxifen in a 
population of women at high risk of developing breast 
cancer. Jack Cuzick and colleagues’ report in The Lancet 
Oncology1 is an important update of the IBIS-I trial. The 
achievement of such long-term follow-up (median 
16 years), especially with more than 74% of participants 
remaining masked to randomisation, is commendable.
An ongoing reduction in the incidence of oestrogen 
receptor-positive breast cancer through 16 years’ 
cumulative median follow-up after 5 years of tamoxifen 
use results in a very favourable number needed to treat 
of only 22 (95% CI 19–26) women receiving tamoxifen 
for 5 years to prevent one case of breast cancer in the 
next 20 years. The ﬁ ndings have clinical implications 
because many women could be spared the psychological 
and physical problems associated with a breast cancer 
diagnosis and related treatment.2 The results build 
on those from eight other selective oestrogen receptor 
modulator chemoprevention trials that showed a 
reduction in breast cancer risk through 10 years’ follow-
up.3 However, the slightly higher number of deaths 
from breast cancer in the tamoxifen group than in the 
placebo group, which persisted beyond 10 years’ follow-
up in IBIS-I, raises a series of questions.
In Cuzick and colleagues’ IBIS-I update, 99 fewer 
breast cancers occurred in the tamoxifen group than 
in the placebo group (251 [7%] in 3579 vs 350 [10%] 
in 3575 respectively; hazard ratio [HR] 0·71 [95% CI 
0·60–0·83], p<0·0001), but surprisingly, there were 
ﬁ ve more deaths from breast cancer in the tamoxifen 
group than in the placebo group (31 vs 26; odds ratio 
1·19 [95% CI 0·68–2·10], p=0·8). After 10 years’ follow-
up, the discordance between the eﬀ ect of tamoxifen on 
breast cancer incidence and deaths from breast cancer 
was more pronounced (18 deaths in the tamoxifen 
group vs nine with placebo; odds ratio 2·00 [95% CI 
0·85–5·06], p=0·08]), although it is important to note 
that this was not signiﬁ cantly diﬀ erent. To resolve such 
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diﬀ erences is not easy, since the authors state that the 
survival results could not be attributed to diﬀ ering 
menopausal hormone therapy use or oestrogen 
receptor-negative disease.1 
The IBIS-I trial was undertaken when determination of 
HER2 status was not possible. Since endocrine therapy 
is less eﬀ ective in oestrogen receptor-positive, HER2-
positive advanced breast cancer4 than in oestrogen 
receptor-positive, HER2-negative disease, could a 
diﬀ erential distribution of HER2-positive cases, under 
the inﬂ uence of tamoxifen therapy, have aﬀ ected the 
breast cancer survival ﬁ ndings? This important issue 
needs to be addressed.
The IBIS-I ﬁ ndings contrast with those from tamoxifen 
use in the adjuvant setting where, in women with early-
stage oestrogen receptor-positive disease, at 15 years 
of follow-up after 5 years of tamoxifen use, congruence 
was recorded between tamoxifen’s eﬀ ect on breast 
cancer recurrence (relative risk [RR] 0·53 [SE 0·03]) and 
on deaths from the disease (RR 0·71 [SE 0·05]).5
Even in a trial that enrolled and randomly assigned 
7154 women, the ﬁ ndings about deaths from breast 
cancer could represent the eﬀ ect of chance alone in the 
small sample of 57 deaths that occurred. In this regard, 
although the authors1 cite previous power calculations 
to indicate that more survival events are needed before 
deﬁ nitive assessment, additional events would be unlikely 
to appreciably change the results since the trend is in 
the opposite direction and survival curves that cross are 
unlikely to become positive. Although the magnitude 
and even the existence of breast cancer overdiagnosis 
by screening remains controversial,6,7 could tamoxifen 
treatment in IBIS-I have been selectively preventing breast 
cancers with extremely favourable prognoses? Additional 
follow-up of the other selective oestrogen receptor 
modulator prevention trials might address this issue.
In IBIS-I, tamoxifen was less eﬀ ective in reducing 
breast cancer risk in women who used menopausal 
hormone therapy than in those who did not use 
hormone therapy.1 Menopausal hormone therapy8 and 
tamoxifen3,5 can both aﬀ ect breast cancer and other 
chronic diseases, and their combined eﬀ ect on most 
of these illness is unknown. In the Women’s Health 
Initiative randomised trials, oestrogen plus progestin, 
in the form of conjugated equine oestrogen, increases 
breast cancer incidence and deaths from breast cancer, 
whereas oestrogen alone reduces breast cancer 
incidence and deaths.9 Additionally, these hormone 
therapy regimens also have eﬀ ects on other cancers.9 
Future IBIS-I subgroup analyses should separate the 
eﬀ ects of these two hormone therapy regimens.
Overall survival is a reasonable endpoint for advanced 
breast cancer and adjuvant trials. In prevention trials 
that incorporate analyses after long-term follow-up, 
an increasingly larger proportion of deaths from other 
causes occur, years or decades after interventions are 
stopped. In the current IBIS-I report, only 57 (15%) 
of 389 total deaths were related to breast cancer. 
Alternative endpoints should be considered for future 
chemoprevention trials, especially for those that enrol 
older participants similar to those entered in IBIS-I.
At present, despite positive ﬁ ndings in terms of their 
eﬀ ect on breast cancer incidence, the use of selective 
oestrogen receptor modulators for breast cancer 
chemoprevention in clinical practice is very infrequent.10 
The discordance between tamoxifen’s eﬀ ects on breast 
cancer incidence and outcome noted in the IBIS-I update 
could merely represent the eﬀ ects of chance alone, or 
alternatively might indicate that tamoxifen mainly 
decreases the incidence of cancers with a very favourable 
prognosis, increases cancers with unfavourable 
outcomes, or both. How these alternative ideas are 
viewed will determine the eﬀ ect of the IBIS-I update on 
breast cancer chemoprevention practice in the clinic.
Rowan T Chlebowski
Los Angeles BioMedical Research Institute at Harbor-UCLA 
Medical Center, 1024 W Carson Street, Torrance, CA 90502, USA
rowanchlebowski@gmail.com
I have received consulting fees or honoraria from Novartis, Amgen, and 
Genomic Health; fees for participation in review activities for Pﬁ zer and Novo 
Nordisk; payment for lectures from Novartis; and payment for educational 
activities from Educational Concepts Group.
© Chlebowski. Open Access article distributed under the terms of CC BY.
1 Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast 
cancer: extended long-term follow up of the IBIS-I breast cancer prevention 
trial. Lancet Oncol 2014; published online Dec 11. http://dx.doi.
org/10.1016/S1470-2045(14)71171-4.
2 Trentham-Dietz A, Sprague BL, Klein R, et al. Health-related quality of life 
before and after a breast cancer diagnosis. Breast Cancer Res Treat 2008; 
109: 379–87.
3 Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators 
in prevention of breast cancer: an updated meta-analysis of individual 
participant data. Lancet 2013; 381: 1827–34.
4 Chlebowski RT. Strategies to overcome endocrine therapy resistance in 
hormone receptor-positive advanced breast cancer. Clin Invest 2014; 
4: 19–33.
5 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of 
breast cancer hormone receptors and other factors to the eﬃ  cacy of 
adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 
Lancet 2011; 378: 771–84.
Comment
www.thelancet.com/oncology   Vol 16   January 2015 9
6 Bleyer A, Welch HG. Eﬀ ect of three decades of screening mammography on 
breast-cancer incidence. N Engl J Med 2012; 367: 1998–2005.
7 Helvie MA, Chang JT, Hendrick RE, Banerjee M. Reduction in late-stage 
breast cancer incidence in the mammography era: implications for 
overdiagnosis of invasive cancer. Cancer 2014; 120: 2649–56.
8 Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone 
therapy and health outcomes during the intervention and extended 
post-stopping phases of the Women’s Health Initiative randomized trials. 
JAMA 2013; 310: 1353–68.
9 Chlebowski RT, Anderson GL. Menopausal hormone therapy and cancer: 
changing clinical observations of target site speciﬁ city. Steroids 2014; 
90: 53–59.
10 Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and 
raloxifene for breast cancer chemoprevention in 2010. 
Breast Cancer Res Treat 2012; 134: 875–80.
Towards eﬀ ective adjuvant treatment for urothelial cancer
Published Online
December 11, 2014
http://dx.doi.org/10.1016/
S1470-2045(14)71187-8
See Articles page 76
Ze
ph
yr
/S
cie
nc
e 
Ph
ot
o 
Li
br
ar
y 
Data for the eﬃ  cacy of adjuvant chemotherapy in 
urothelial cancer comes from prematurely closed trials 
with poor accrual that have not yielded deﬁ nitive 
conclusions about beneﬁ t. Yet, the potential activity 
reported in these trials has been promising enough to 
encourage investigators to pursue assessment of this 
treatment. In The Lancet Oncology, Cora Sternberg and 
colleagues1 report the results of the EORTC 30994 trial, 
which compared immediate versus deferred cisplatin-
based combination chemotherapy after radical 
cystectomy in patients with urothelial carcinoma of 
the bladder. They found no signiﬁ cant diﬀ erence in the 
study’s primary endpoint of overall survival between 
immediate and deferred chemotherapy (hazard ratio 
[HR] 0·78, adjusted 95% CI 0·56–1·08; p=0·13), but 
immediate chemotherapy did signiﬁ cantly increase 
5-year progression-free survival (HR 0·54, 95% CI 
0·4–0·73; p<0·0001). 
Some might argue against the relevance of this study, 
since neoadjuvant chemotherapy with methotrexate, 
vinblastine, doxorubicin, and cisplatin (MVAC) is the 
proven standard for the treatment of muscle-invasive 
bladder cancer.2 Although these recommendations 
were made more than a decade ago, neoadjuvant 
therapy remains highly underused. The inherent 
toxicity associated with cisplatin-based therapy in 
the typical urothelial cancer population of elderly and 
frail patients ensures that it is unlikely to be given 
to a substantial proportion of patients. Therefore, 
recommendations about adjuvant chemotherapy will 
remain highly relevant either until a non-toxic curative 
therapy is discovered, or until the patients who truly 
beneﬁ t from these potentially toxic regimens can be 
accurately identiﬁ ed.    
Eﬀ orts to improve chemotherapy for urothelial 
cancer date back to the 1980s, when adjuvant 
CISCA (cisplatin, cyclophosphamide, and doxorubicin) 
was reported to have cured a higher proportion of 
patients with bladder cancer than did surgery alone.3 
MVAC arrived soon after with compelling evidence 
supporting the use of this combination in patients 
with pathological T3b or worse disease at surgery,4 
yet insuﬃ  cient numbers of patients or design ﬂ aws 
prevented deﬁ nitive conﬁ rmation of a survival beneﬁ t. 
Additional trials of gemcitabine cisplatin have been 
limited by similar problems.5 
Other chemotherapy combinations for urothelial 
cancer, including those with higher doses of 
ifosfamide,6 have been assessed in the perioperative 
setting, but have not surpassed the outcomes 
achieved with MVAC. Even high-dose MVAC,7 which 
is administered every 2 weeks, has not improved 
survival outcomes, although the improved toxicity 
proﬁ le has supported its use. One potential exception 
is adjuvant gemcitabine, paclitaxel, and cisplatin, 
which was reported to improve survival in a recent 
abstract.8 Perhaps ﬁ nal results from this trial will yield 
the deﬁ nitive conclusions that investigators seek.
Results of Sternberg and colleagues’ study1 suggest 
that adjuvant chemotherapy might beneﬁ t patients 
with node-negative disease. However, most patients in 
this trial did not have adequate lymph-node dissection, 
so this ﬁ nding should be interpreted with caution. An 
alternative conclusion is that patients with inadequate 
lymph-node dissection might be more likely to beneﬁ t 
from adjuvant chemotherapy. Also, many of these 
patients might have been characterised as node-
positive if more lymph nodes had been removed. 
Clearly, additional studies are needed to conﬁ rm this 
ﬁ nding.
In view of the absence of deﬁ nitive success with this 
trial, and admittedly most other trials of adjuvant 
chemotherapy for bladder cancer reported so far, it 
seems unlikely that using a similar framework to design 
